Date: 2014-05-28
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA.
Company: Debiopharm (Switzerland) Curis (USA)
Product: Debio 0932
Action
mechanism: Debio 0932 is a synthetic small molecule that belongs to the HSP90 family inhibitors. It competes with ATP in binding to the N-terminal portion of HSP90 and inactivates the ATPase activity of the chaperone. Inhibition of HSP90 results in an increased degradation of oncogenic proteins resulting in tumor growth inhibition.
Disease: non-small cell lung cancer (NSCLC) renal cell carcinoma (RCC)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 8, 2014,Curis and Debiopharm have announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients. In a high throughput combination screen performed with six different human NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule and mTOR/ Akt targeting agents across all six cell lines. Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human xenograft models of NSCLC and RCC.
